Literature DB >> 23568491

SF3B1 mutations in chronic lymphocytic leukemia.

Youzhong Wan1, Catherine J Wu.   

Abstract

SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre-mRNA splicing has been detected in CLL cases with SF3B1 mutations. Although the causative link between SF3B1 mutation and CLL pathogenesis remains unclear, several lines of evidence suggest SF3B1 mutation might be linked to genomic stability and epigenetic modification.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568491      PMCID: PMC3674664          DOI: 10.1182/blood-2013-02-427641

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Molecular architecture of the multiprotein splicing factor SF3b.

Authors:  Monika M Golas; Bjoern Sander; Cindy L Will; Reinhard Lührmann; Holger Stark
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

2.  Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.

Authors:  Mariangela Greco; Daniela Capello; Alessio Bruscaggin; Valeria Spina; Silvia Rasi; Sara Monti; Carmela Ciardullo; Stefania Cresta; Marco Fangazio; Gianluca Gaidano; Robin Foà; Davide Rossi
Journal:  Hematol Oncol       Date:  2012-03-29       Impact factor: 5.271

3.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1.

Authors:  Kyoichi Isono; Yoko Mizutani-Koseki; Toshihisa Komori; Marion S Schmidt-Zachmann; Haruhiko Koseki
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

4.  A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site.

Authors:  O Gozani; J Potashkin; R Reed
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

Review 5.  Initial splice-site recognition and pairing during pre-mRNA splicing.

Authors:  R Reed
Journal:  Curr Opin Genet Dev       Date:  1996-04       Impact factor: 5.578

6.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 7.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

Authors:  Mario Cazzola; Marianna Rossi; Luca Malcovati
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

8.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

9.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

10.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Authors:  David G Oscier; Matthew J J Rose-Zerilli; Nils Winkelmann; David Gonzalez de Castro; Belen Gomez; Jade Forster; Helen Parker; Anton Parker; Anne Gardiner; Andrew Collins; Monica Else; Nicholas C P Cross; Daniel Catovsky; Jonathan C Strefford
Journal:  Blood       Date:  2012-10-18       Impact factor: 22.113

View more
  49 in total

Review 1.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

Review 2.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 3.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Romain Guièze; Catherine J Wu
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

4.  Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Authors:  Alicia Báez; José I Piruat; Teresa Caballero-Velázquez; Luís I Sánchez-Abarca; Isabel Álvarez-Laderas; M Victoria Barbado; Estefanía García-Guerrero; África Millán-Uclés; Jesús Martín-Sánchez; Mayte Medrano; José Antonio Pérez-Simón
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 5.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

Review 6.  Evolving understanding of the CLL genome.

Authors:  Michaela Gruber; Catherine J Wu
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

7.  Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex.

Authors:  Sarah Loerch; Alexandre Maucuer; Valérie Manceau; Michael R Green; Clara L Kielkopf
Journal:  J Biol Chem       Date:  2014-05-02       Impact factor: 5.157

8.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

Review 9.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

10.  A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Authors:  Fernando J de Miguel; María J Pajares; Elena Martínez-Terroba; Daniel Ajona; Xabier Morales; Ravi D Sharma; Francisco J Pardo; Ana Rouzaut; Angel Rubio; Luis M Montuenga; Ruben Pio
Journal:  Mol Oncol       Date:  2016-08-09       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.